HF5156
Price for prescription drugs subject to the Medicare Drug Price Negotiation Program established.
Legislative Session 94 (2025-2026)
Related bill: SF5302
Bill text
(underlined = new law, struck through = current law the bill removes)
Versions
1.1A bill for an act
1.2relating to health care; establishing prices for prescription drugs subject to the
1.3Medicare Drug Price Negotiation Program; proposing coding for new law in
1.4Minnesota Statutes, chapter 62Q.
1.5BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
1.6Section 1. new text begin [62Q.586] MAXIMUM FAIR PRICE FOR CERTAIN PRESCRIPTION new text end
1.7 new text begin DRUGS. new text end
1.8 new text begin Subdivision 1. Definitions. (a) For purposes of this section, the following terms have new text end
1.9 new text begin the meanings given. new text end
1.10 new text begin (b) "Manufacturer" has the meaning given in section 151.01, subdivision 14a. new text end
1.11 new text begin (c) "Maximum fair price" means the maximum fair price established for a prescription new text end
1.12 new text begin drug by the United States Department of Health and Human Services under United States new text end
1.13 new text begin Code, title 42, section 1320f-3. new text end
1.14 new text begin (d) "NADAC" means the national average drug acquisition cost. new text end
1.15 new text begin (e) "Pharmacy benefit manager" means a pharmacy benefit manager licensed under new text end
1.16 new text begin chapter 62W. new text end
1.17 new text begin (f) "Referenced drug" means a prescription drug subject to a maximum fair price. new text end
1.18 new text begin Subd. 2. Maximum fair price requirements. (a) A manufacturer is prohibited from new text end
1.19 new text begin accepting payment at an amount higher than the maximum fair price for the sale of a new text end
1.20 new text begin referenced drug intended for use by individuals in the state in person, by mail, or by any new text end
1.21 new text begin other means, plus any applicable pharmacy dispensing fees and provider administration new text end
1.22 new text begin fees. new text end
2.1 new text begin (b) A health plan and a pharmacy benefit manager must not reimburse a pharmacy for new text end
2.2 new text begin a referenced drug at an amount that is less than the maximum fair price or the NADAC, new text end
2.3 new text begin whichever is greater, plus any established dispensing fee for the referenced drug. No new text end
2.4 new text begin provision of this section shall be construed to prevent a pharmacy from receiving a dispensing new text end
2.5 new text begin fee above the maximum fair price for a referenced drug. new text end
2.6 new text begin (c) A health plan and a pharmacy benefit manager must, upon request, provide to the new text end
2.7 new text begin Prescription Drug Affordability Board established under section 62J.87, financial information, new text end
2.8 new text begin including administrative fees, formulary management fees, rebate retention, network access new text end
2.9 new text begin fees, shared savings programs, and the total and final payment details, including the ingredient new text end
2.10 new text begin cost and any dispensing fee, paid or payable by the health plan or pharmacy benefit manager new text end
2.11 new text begin to a pharmacy for dispensing a referenced drug. The information must include all associated new text end
2.12 new text begin fees, adjustments, and reconciliations. The information is subject to the data requirements new text end
2.13 new text begin under section 62J.91, subdivision 3. new text end
2.14 new text begin Subd. 3. Prohibition on withdrawing a referenced drug from sale. (a) A manufacturer new text end
2.15 new text begin is prohibited from removing a drug from sale or distribution in the state for the purpose of new text end
2.16 new text begin avoiding the impact of the rate limitations in this section unless the manufacturer provides new text end
2.17 new text begin a written notice of withdrawal to the commissioner of health within 180 days prior to the new text end
2.18 new text begin withdrawal. new text end
2.19 new text begin (b) The commissioner of health shall assess a penalty on any manufacturer that has new text end
2.20 new text begin withdrawn a referenced drug from sale or distribution in the state in violation of paragraph new text end
2.21 new text begin (a). With respect to each referenced drug withdrawn by the manufacturer, the civil penalty new text end
2.22 new text begin shall be equal to the greater of: new text end
2.23 new text begin (1) $100,000; or new text end
2.24 new text begin (2) the total amount of annual savings for the referenced drug, as determined by the new text end
2.25 new text begin Prescription Drug Affordability Board. new text end
2.26 new text begin EFFECTIVE DATE. This section is effective January 1, 2027. new text end
Bill information comes from public records published by the Office of the Revisor of Statutes, the Minnesota House and the Minnesota Senate. AI summaries are written by MinneSlate and are not official. MinneSlate is independent and is not affiliated with the State of Minnesota or the Minnesota Legislature.
Progress through the legislative process
In Committee
Sponsors
- Rep. Michael Howard (DFL)
- Rep. Leigh Finke (DFL)
- Rep. Steve Elkins (DFL)
- Rep. Anquam Mahamoud (DFL)
- Rep. Ethan Cha (DFL)
- Rep. Liz Reyer (DFL)
- Rep. Kristin Bahner (DFL)
- Rep. Brad Tabke (DFL)
- Rep. Matt Norris (DFL)
- Rep. Lucille Rehm (DFL)
- Rep. Kari Rehrauer (DFL)
- Rep. Kaela Berg (DFL)
- Rep. Alicia Kozlowski (DFL)
- Rep. Kristi Pursell (DFL)
- Rep. Peter Johnson (DFL)
- Rep. Larry Kraft (DFL)
- Rep. Mike Freiberg (DFL)
- Rep. Bianca Virnig (DFL)
- Rep. Tina Liebling (DFL)
- Rep. Cheryl Youakim (DFL)
- Rep. Emma Greenman (DFL)
- Rep. Sandra Feist (DFL)
- Rep. Alexander Falconer (DFL)
- Rep. Sydney Jordan (DFL)